Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

F 573

Drug Profile

F 573

Alternative Names: CV-1013; EP-1013; F-573; MX-1013

Latest Information Update: 04 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EpiCept Corporation
  • Developer EpiCept Corporation; GNI
  • Class Antineoplastics; Dipeptides; Small molecules
  • Mechanism of Action Caspase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Liver failure
  • No development reported Transplant rejection; Viral hepatitis
  • Discontinued Liver disorders; Multiple organ failure; Myocardial infarction; Septic shock; Stroke

Most Recent Events

  • 04 Feb 2019 GNI plans a phase I trial for Liver failure in China (GNI pipeline, February 2019)
  • 01 Feb 2019 Preclinical trials in Liver failure in China (IV) before February 2019 (GNI pipeline, February 2019)
  • 01 Feb 2019 Preclinical trials in Liver failure in China (PO) before February 2019 (GNI pipeline, February 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top